BioStock Investor Pitch: Prolevi Bio
Privately-owned Prolevi Bio’s goal is to improve the treatment of hypothyroidism, a common condition involving a lack of thyroid hormone. The company has developed a method that releases medicine based on the patient’s circadian rhythm. According to Prolevi Bio, this should improve the effect of the drug, something that CEO Sahil Gupta explains more about in a company presentation in BioStock’s studio.
Watch Prolevi Bio’s CEO Sahil Gupta present the company below.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.